1. Home
  2. MTA vs BWAY Comparison

MTA vs BWAY Comparison

Compare MTA & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Metalla Royalty & Streaming Ltd.

MTA

Metalla Royalty & Streaming Ltd.

HOLD

Current Price

$7.51

Market Cap

766.4M

Sector

N/A

ML Signal

HOLD

Logo BrainsWay Ltd.

BWAY

BrainsWay Ltd.

HOLD

Current Price

$16.47

Market Cap

674.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MTA
BWAY
Founded
1983
2003
Country
Canada
Israel
Employees
N/A
129
Industry
Medical/Dental Instruments
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
766.4M
674.2M
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
MTA
BWAY
Price
$7.51
$16.47
Analyst Decision
Hold
Strong Buy
Analyst Count
1
2
Target Price
$9.00
$13.25
AVG Volume (30 Days)
356.7K
127.0K
Earning Date
05-15-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$81.63
$309.69
Revenue Next Year
$62.44
$26.21
P/E Ratio
N/A
$81.98
Revenue Growth
N/A
N/A
52 Week Low
$2.83
$9.98
52 Week High
$9.25
$26.63

Technical Indicators

Market Signals
Indicator
MTA
BWAY
Relative Strength Index (RSI) 58.91 53.94
Support Level $7.08 $14.56
Resistance Level $7.73 $16.63
Average True Range (ATR) 0.33 0.61
MACD 0.11 -0.00
Stochastic Oscillator 80.43 53.44

Price Performance

Historical Comparison
MTA
BWAY

About MTA Metalla Royalty & Streaming Ltd.

Metalla Royalty & Streaming Ltd is a precious metals royalty and streaming company, which engages in the acquisition and management of precious metal royalties, streams, and similar production-based interests. It's a pure-play gold and silver streaming and royalty company. It generates revenue from royalties, streams, and other interests.

About BWAY BrainsWay Ltd.

BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.

Share on Social Networks: